SOURCE: MOTUS GI Technologies, Ltd.

Motus GI Technologies, Ltd.

November 28, 2016 07:30 ET

Motus GI Appoints James J. Martin as Chief Financial Officer

TIRAT CARMEL, ISRAEL--(Marketwired - November 28, 2016) - Motus GI, a medical device company dedicated to improving colonoscopy outcomes and experiences, today announced the appointment of James J. Martin as Chief Financial Officer. Mr. Martin has nearly 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded medical device companies.

"We welcome Jim to the Motus GI team as we grow the organization to support the commercial roll-out of Pure-Vu System," said Mark Pomeranz, CEO of Motus GI. "His broad experience with commercial healthcare companies will be extremely valuable as we launch the Pure-Vu System in both the in-hospital and outpatient settings, providing physicians with new options to cleanse the colon intra-procedurally to achieve visualization of the colon mucosa during colonoscopy."

Most recently, Mr. Martin was the Chief Financial Officer of VBI Vaccines, Inc. (formerly SciVac Therapeutics, Inc.), a dual listed Canadian TSX and NASDAQ commercial vaccine company, where he led the company in the successful completion of a merger in July 2015 and an acquisition in May 2016. Since 2010, Mr. Martin has also served as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc., a company marketing non-invasive medical devices. From 2014 to 2015, Mr. Martin served as Chief Financial Officer of the NASDAQ listed Vapor Corp, Inc. after serving as Chief Financial Officer of NYSE listed TransEnterix, Inc. from 2010 to 2013. Earlier in his career, Mr. Martin held finance positions at Aero Pharmaceuticals, AAR Aircraft Services and Systems Products International. Mr. Martin was also an Operations Specialist with the U.S. Navy from 1985 to 1990. Mr. Martin holds an undergraduate degree in business administration and an MBA from Barry University in Miami and is a Certified Public Accountant.

About Colonoscopy

Colonoscopy is one of the most common medical procedures performed. Approximately forty percent of colonoscopies are conducted as the standard of care for detecting colorectal cancer (CRC), while the remaining 60% are focused on diagnosis and surveillance of patients with gastrointestinal issues such as bleeding, inflammatory bowel disease and motility challenges.

About Motus GI

Motus GI is a medical technology company based in Tirat Carmel, Israel. Founded in 2008, the company is focused on the development and commercialization of the Pure-Vu System to improve the colonoscopy experience for physicians, patients and payers by enhancing the quality and cost-effectiveness of the exam. The Pure-Vu System is indicated to connect to standard colonoscopes to perform intra-procedural cleaning of a poorly prepared colon, thereby reducing the sole dependency on a successful pre-procedural prep regimen to gain clear visualization of the colon mucosa. For more information, visit

Forward-Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact Information